Trial Profile
Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2012, according to ClinicalTrials.gov record.
- 29 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.